soliris
alexion europe sas - ekulizumab - hemoglobinurie, paroxysmální - imunosupresiva - přípravek soliris je indikován u dospělých a dětí k léčbě:paroxysmální noční hemoglobinurie (pnh). důkazy o klinické prospěšnosti je prokázána u pacientů s hemolýza s klinickým příznakem(s) svědčí o vysoké aktivity nemoci, bez ohledu na to, transfúze historie (viz bod 5. atypický hemolyticko-uremický syndrom (ahus). přípravek soliris je indikován u dospělých k léčbě:Žáruvzdorné generalizované myasthenia gravis (gmg) u pacientů, kteří jsou anti-acetylcholinové receptory (achr) protilátky-pozitivní (viz bod 5. neuromyelitis optica spectrum disorder (nmosd) u pacientů, kteří jsou anti-aquaporin-4 (aqp4) protilátky-pozitivní s recidivující průběh onemocnění.
terralon la 200 mg/ml injekční roztok
virbac sa - oxytetracyklin - injekční roztok - tetracykliny - prasata, ovce, skot
baytril one 100 mg/ml injekční roztok
bayer animal health gmbh - enrofloxacin - injekční roztok - fluorochinolony - skot, prasata
ceftiocyl flow 50 mg/ml injekční suspenze
vetoquinol s.r.o. (2) - ceftiofur - injekční suspenze - cefalosporiny třetí generace - skot, prasata
cenflox 100 mg/ml injekční roztok
cena visa s.a. - enrofloxacin - injekční roztok - fluorochinolony - prasata, skot
tuloxxin 100 mg/ml injekční roztok
krka d.d. novo mesto - tulathromycin - injekční roztok - makrolidy - prasata, skot, ovce
ultomiris
alexion europe sas - ravulizumab - hemoglobinurie, paroxysmální - selektivní imunosupresiva - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.
enrocat flavour 25 mg/ml perorální suspenze
livisto int'l, s.l. - enrofloxacin - perorální suspenze - fluorochinolony - kočky
tuloxxin 25 mg/ml injekční roztok
krka d.d. novo mesto - tulathromycin - injekční roztok - makrolidy - prasata
tyljet 200 mg/ml injekční roztok
ceva animal health slovakia s.r.o. - tylosin - injekční roztok - makrolidy - skot, prasata